UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Annals of oncology, 2021-06, Vol.32 (6), p.746-756

2021

Volltextzugriff (PDF)

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii133

2018

Volltextzugriff (PDF)

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008

Annals of oncology, 2009-06, Vol.20 (suppl-7), p.vii1-vii6

2009

Volltextzugriff (PDF)

Pancreas cancer on the rise: are we up to the challenge?

JNCI : Journal of the National Cancer Institute, 2013-11, Vol.105 (22), p.1675-1676

2013

Volltextzugriff (PDF)

Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer

Annals of oncology, 2018-10, Vol.29, p.viii189-viii190

2018

Volltextzugriff (PDF)

Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC)

Annals of oncology, 2018-10, Vol.29, p.viii716-viii716

2018

Volltextzugriff (PDF)

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

Annals of oncology, 2018-11, Vol.29, p.ix23-ix23

2018

Volltextzugriff (PDF)

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

ESMO open, 2024-04, Vol.9 (4), p.102961-102961, Article 102961

2024

Volltextzugriff (PDF)

The epidermal growth factor receptor as a target for colorectal cancer therapy

Seminars in oncology, 2005-02, Vol.32 (1), p.52-60

2005

Volltextzugriff (PDF)

A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296)

Oncology, 2000-01, Vol.58 (3), p.215-218

2000

Volltextzugriff (PDF)

Warfarin—5‐FU Interaction — A Consecutive Case Series

Pharmacotherapy, 1999-12, Vol.19 (12), p.1445-1449

1999

Volltextzugriff (PDF)

A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors

Investigational new drugs, 1998, Vol.16 (4), p.325-330

1998

Volltextzugriff (PDF)

5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: An eastern cooperative oncology group phase II study (E1889)

American journal of clinical oncology, 1998-04, Vol.21 (2), p.171-176

1998

Volltextzugriff (PDF)

612PSPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

LBA23Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

567PResults of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

682PPhase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

445PDDurability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

409OLarotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

69OLarotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

Annals of oncology, 2018-11, Vol.29 (suppl_9)

2018

Volltextzugriff (PDF)

Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297

Journal of clinical oncology, 2002-08, Vol.20 (15), p.3270-3275

2002

Volltextzugriff (PDF)

Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial

Journal of clinical oncology, 2003-06, Vol.21 (11), p.2059-2069

2003

Volltextzugriff (PDF)

Complete response to neoadjuvant chemoradiation therapy for esophageal cancer does not confer a survival advantage

Annals of surgical oncology, 2004-02, Vol.11 (S2), p.S55-S55

2004

Volltextzugriff (PDF)

Chemotherapy for resectable and advanced pancreatic cancer

Oncology (Williston Park, N.Y.), 2001-10, Vol.15 (10), p.1241

2001

Volltextzugriff (PDF)

The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona

Annals of oncology, 2014-06, Vol.25, p.ii1-ii4

2014

Volltextzugriff (PDF)

1 – 25 von 1.674

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.368)
Mit Volltextzugriff
(1.256)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.519)
Französisch
(110)
Deutsch
(45)
Japanisch
(5)
Russisch
(2)
Chinesisch
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(933)
Life Sciences & Biomedicine
(675)
Humans
(492)
Biological And Medical Sciences
(318)
Male
(283)
Female
(267)
Medical Sciences
(246)
Physical Sciences
(232)
Animals
(185)
Adult
(180)
Middle Aged
(166)
Physics
(160)
Aged
(127)
Oncology
(125)
Pharmacology. Drug Treatments
(84)
Fundamental And Applied Biological Sciences. Psychology
(79)
Physics, Particles & Fields
(76)
Chemistry
(73)
Particle Physics
(69)
General & Internal Medicine
(62)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008

Pancreas cancer on the rise: are we up to the challenge?

Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer

Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC)

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

The epidermal growth factor receptor as a target for colorectal cancer therapy

A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296)

Warfarin—5‐FU Interaction — A Consecutive Case Series

A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors

5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: An eastern cooperative oncology group phase II study (E1889)

612PSPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase

LBA23Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC)

567PResults of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer

682PPhase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses

445PDDurability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

409OLarotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

69OLarotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297

Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial

Complete response to neoadjuvant chemoradiation therapy for esophageal cancer does not confer a survival advantage

Chemotherapy for resectable and advanced pancreatic cancer

The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona

Suchergebnisse filtern